LENZ Therapeutics, Inc. (LENZ)
- Previous Close
25.87 - Open
26.34 - Bid 18.63 x 200
- Ask 32.01 x 200
- Day's Range
25.01 - 26.34 - 52 Week Range
14.42 - 38.93 - Volume
22,012 - Avg. Volume
239,498 - Market Cap (intraday)
705.907M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-2.34 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
44.88
LENZ Therapeutics, Inc. operates as a biopharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include LNZ100 and LNZ101 which are in Phase III clinical trials for the treatment of presbyopia. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
www.lenz-tx.comRecent News: LENZ
View More
Performance Overview: LENZ
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: LENZ
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: LENZ
View MoreValuation Measures
Market Cap
728.14M
Enterprise Value
520.49M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
3.57
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-25.64%
Return on Equity (ttm)
-38.94%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-49.77M
Diluted EPS (ttm)
-2.34
Balance Sheet and Cash Flow
Total Cash (mrq)
209.03M
Total Debt/Equity (mrq)
0.68%
Levered Free Cash Flow (ttm)
-40.65M